Comments
Commented by Juliane Zielonka on January 11th, 2024 | 07:15 CET
From innovative cancer therapy to menopause: How Defence Therapeutics, Bayer and NVIDIA are reshaping the medical landscape
The global prevalence of lung cancer as the second most common cancer and the challenges associated with it have led Defence Therapeutics to develop an innovative solution. Through unconventional nasal delivery, following the motto "through the nose to the lungs", the non-hormonal drug enables the precise distribution of the active ingredient. This advance could replace conventional surgical procedures for lung cancer and open up new avenues in cancer therapy. Bayer aims to generate EUR 1 billion in sales in women's health. The drug aims to alleviate the many symptoms of menopause effectively and opens up new revenue prospects for Bayer in the field of women's health. NVIDIA brings pharmaceutical research into the digital age. BioNeMo, a generative AI platform, enables research and development teams to represent drugs directly on the computer. Discover the opportunities emerging for investors now.
Read
Commented by Fabian Lorenz on January 11th, 2024 | 07:00 CET
Evotec is in the analyst check, Tui with Wanderlust, and another 100% gain for Manuka Resources?
The Evotec stock is currently not for the faint-hearted. After the resignation of the long-serving board member caused uncertainty, the biotech company was able to reassure investors with a milestone payment. Analysts are speaking out and expressing their opinions, and a real "bull" is among them. And what about Manuka Resources? At the beginning of December, news about an exciting project for battery metals caused a jump in the share price. Is it now worth getting in after the consolidation? The Tui share has also recently consolidated after a 50% gain within a few weeks. Analysts' price targets for the tourism company's shares vary widely. Hold or buy?
Read
Commented by Juliane Zielonka on January 10th, 2024 | 12:00 CET
Cardiol Therapeutics, Morphosys, BioNTech - Who will switch to the fast lane in 2024?
The life science and biotech sector has a few aces up its sleeve in 2024. Cardiol Therapeutics announces a significant clinical milestone, with over 50% of participants now enrolled in the ARCHER trial for acute myocarditis. MorphoSys, a cancer drug company, is developing an oral therapy specifically for proteins against myelofibrosis with the promising compound "pelabresib". However, analysts disagree on the share valuation. Top dog BioNTech is planning sales of EUR 3 billion in 2024, also focusing on oncology. CEO Uğur Şahin emphasizes the strategic scaling of the cancer therapy business by 2025 and initial market launches by 2026. Who will use 2024 to move into the fast lane?
Read
Commented by Fabian Lorenz on January 10th, 2024 | 07:30 CET
Bayer with a blockbuster! Vonovia weak! And how are Desert Gold shares doing?
While the DAX, Dow & Co. started the new year weakly, Bayer shares are holding up surprisingly well and can maintain the price gains from the end of 2023. The share price is being supported by positive news. A new blockbuster is waiting in the wings. Vonovia shares, on the other hand, are suffering from profit-taking, although analysts see further upside potential. Is concrete gold celebrating a comeback? And what about real gold? The price has weakened recently, but analysts believe USD 2,200 per ounce is possible, and central banks continue buying heavily. This should benefit not only the major gold producers but also low-cost explorers such as Desert Gold.
Read
Commented by Armin Schulz on January 10th, 2024 | 07:15 CET
Evotec, Defense Metals, PayPal - There is movement here. Where is it worth getting in?
In the dynamic environment of the stock market, it is often significant movements in individual shares that attract the attentive eye of investors. Volatile securities lure investors with the promise of quick profits, but they may signal more than just short-term market fluctuations. When stocks start to move and deviate from their usual trading patterns, it can indicate fundamental changes in the business environment, industry-specific developments or macroeconomic turning points. For the savvy investor, this might be the opportune moment when promising entry opportunities reveal themselves. However, caution is advised: Only those prepared to look behind the scenes and analyze the factors behind the volatility can truly profit from market movements.
Read
Commented by Stefan Feulner on January 9th, 2024 | 07:00 CET
ExxonMobil, Prospera Energy, Shell - Falling profits and new opportunities in black gold
The fall in energy prices led to a significant drop in inflation. Consequently, the colossal profits of oil giants, such as Chevron, Exxon, and PB, also melted away. As a result, the stock prices of these companies corrected, potentially providing long-term investors with a new buying opportunity. Many experts agree that in the long term, the decline in black gold is likely just a temporary dip in its overall upward trend, which should lead to significantly higher price targets in the coming years.
Read
Commented by André Will-Laudien on January 9th, 2024 | 06:45 CET
Despite farmers' strike - rally with hydrogen and GreenTech ahead in 2024! Nel ASA, First Hydrogen, Nordex and Siemens Energy
While the DAX and NASDAQ are soaring from high to high, some stocks are completely falling by the wayside. We are talking about countless GreenTech stocks that have missed the boat in terms of profitability. In the 2023 investment year, solar, wind and hydrogen companies suffered losses of between 50% and 80%. Investors responded to the lack of profits with a collective exodus and offset the share price gains of the last three years. The decisions taken at the World Climate Conference in Dubai could now be the starting signal for a medium-term rebound attempt. Those who analyze the situation closely may arrive at surprising insights.
Read
Commented by Stefan Feulner on January 8th, 2024 | 07:15 CET
Infineon, Globex Mining, Volkswagen AG - Excellent general conditions
The year got off to a bumpy start. The DAX, Dow Jones and Co. started the first trading week of the year with losses. The fact that several traders were still on their well-earned Christmas vacations and volumes were low led to high fluctuations in both directions. Chip stocks, in particular, suffered due to a sales warning from the US. In contrast, gold and commodity stocks benefited due to their stable underlying values. This positive trend could continue after the corrections of the past year.
Read
Commented by André Will-Laudien on January 8th, 2024 | 07:00 CET
Start of the year with GreenTech hype! Will BYD, Klimat X Developments, Plug Power and Freyr Battery deliver now?
The year 2024 will be the next test for GreenTech shares. In the past investment year, despite bullish markets, they were the biggest losers in the portfolio. Plug Power and Freyr Battery incurred the most significant negative returns, ranging from 70 to 80%, but BYD and Klimat X also saw a slight decline. However, with the resolutions passed in Dubai and new government climate protection programs, things could pick up again in the new year. But who can win the coveted government contracts? We analyze the opportunities and risks.
Read
Commented by Juliane Zielonka on January 5th, 2024 | 08:45 CET
Altech Advanced Materials, BYD, and Rheinmetall - Growth drivers: innovation, market power and strong cash flow
Made in Germany stands for durability. Battery storage pioneer Altech Advanced Materials stands out as a German company with innovative material developments that can radically change electromobility and stationary energy storage with a 30% increase in efficiency. Meanwhile, the Chinese car manufacturer BYD has established itself as the leader in the electric vehicle market, surpassing Tesla in terms of sales figures in Q4/23. Rheinmetall is also strongly expanding its electromobility divisions and can look forward to a 3-digit million dollar order in its ubiquitous division. Find out who is setting new standards and shaping the future here.
Read